

People

A sample of goings-on in and around the biotech and pharmaceutical industry.



Richard J. Wenstrup (photo) has been named chief medical officer of Epic Sciences. He was previously chief medical officer for Oxford Immunotec, where he oversaw R&D, product development, and regulatory, medical and clinical affairs. From 2006 to 2017 he served as chief medical officer for Myriad Genetics, where he built and led the clinical and medical affairs team to support a multi-fold increase in revenue during his tenure.

Epic's president and CEO Lloyd Sanders says, "Rick brings a wealth of clinical and oncology leadership experience to Epic Sciences, as an executive in the global diagnostic industry, a physician and tenured professor, and is an important addition to our leadership team. His extensive clinical background in oncology, genetics and pharmacogenomics in both the US and international markets strengthens our organization's capabilities as we advance our leading Functional Cell Profiling technology and programs into the clinic, leveraging our clinical expertise in biomarker strategies and patient selection."

The International Service for the Acquisition of Agri-biotech Applications has announced the appointment of **Mahaletchumy Arujanan** as the new ISAAA global coordinator. Arujanan currently serves as executive director of the Malaysian Biotechnology Information Centre.

Copenhagen-based Zealand Pharma has appointed **Emmanuel Dulac** as CEO. Dulac has 25 years of experience in the pharma industry, most recently serving as chief commercial officer at Alnylam Pharmaceuticals.

Louise O. Fresco has joined the board of directors of Syngenta as an independent non-executive director. She is currently president of Wageningen University & Research in the Netherlands, and previously spent ten years as assistant director-general of the Food and Agriculture Organization of the UN.

Crescendo Biologics has promoted current CFO **Theodora Harold** to CEO, succeeding **Peter Pack**. Harold joined Crescendo in October 2016. She previously held finance roles with PsiOxus Therapeutics, Mission Therapeutics, OrthoMimetics and Cytomyx Holdings.

CANbridge Pharmaceuticals has appointed **Glenn Hassan** as CFO and chief business officer and **Gerald F. Cox** as chief development strategist and interim chief medical officer. Hassan comes to CANbridge from China Renaissance Capital, where he was director, cross border healthcare investment banking. Cox was most recently an

independent consultant and previously served as chief medical officer for Editas Medicine.

WuXi AppTec has appointed **Frederick H. Hausheer** chief medical officer. Hausheer has more than 30 years' experience in global oncology clinical drug development and translational science and medicine. Prior to joining WuXi, he was the founder and chairman of BioNumerik Pharmaceuticals.

Verve Therapeutics, a startup aiming to develop CRISPR gene editing therapies for heart disease, has appointed **Sekar Kathiresan** as CEO beginning in July. Kathiresan was previously director of the Center for Genomic Medicine at Massachusetts General Hospital.

Inscripta has announced the appointment of **Ron McGrath** as CFO. McGrath has held leadership and financial roles for more than 25 years in the biotech and IT industries, most recently serving as vice president of finance at Illumina.

Synlogic has named **Scott Plevy** CSO. Plevy most recently served as vice president, gastroenterology disease area leader and IL-23 pathway leader at Janssen Research & Development.

Scott Requadt has been named CEO of Talaris Therapeutics (formerly Regenerex). Requadt was part of the investment team of Clarus Funds (now Blackstone Life Sciences) for 13 years, having most recently served as managing director. He remains a venture partner with Blackstone Life Sciences.

Paragon Biosciences has announced today the appointment of **James (Jim) Robinson** as president and COO. Robinson joins Paragon from Alkermes, where he was president and COO. Previously, he served as president of Americas operations at Tokyo-based Astellas Pharma.



Metrion Biosciences has announced the appointment of **Andrew Southan** (photo) as CEO. Southan was previously the company's COO.

He joined Metrion as head of commercial operations in October 2016 after holding leadership roles at CeNeS Pharmaceuticals, Ionix Pharmaceuticals, BioFocus and Charles River Laboratories.

Kymab has appointed **Simon Sturge** as CEO, succeeding **David Chiswell**, who will remain a scientific adviser to the company. Sturge joins Kymab from Merck KGaA, where he was executive vice president global strategy, business development & global operations. Previously, he was COO of Merck Healthcare.

Carsten Ullrich has been named director of artificial intelligence at Centogene, which uses AI to discover new therapeutic insights and accelerate biomarker development. He most recently served as an associate head of a research lab and senior researcher at the German Research Center for Artificial Intelligence.

Obsidian Therapeutics has announced that **Paul K. Wotton** will succeed **Michael Gilman** as CEO. Wotton most recently served as the founding president and CEO of Sigilon Therapeutics. Previously, he was president and CEO of Ocata Therapeutics until its acquisition by Astellas Pharma, where he was also co-chairman of the office of integration. Gilman will focus on his new role as full-time CEO and chairman of Arrakis Therapeutics; he will continue to serve on Obsidian's board of directors.

Published online: 4 June 2019
<https://doi.org/10.1038/s41587-019-0148-5>